Core Viewpoint - The approximately 45% correction in Hims & Hers Health (HIMS) presents a potential investment opportunity for those who missed the rally in 2024-25 [1] Group 1: Market Analysis - The markets have experienced a significant downturn, which may create favorable conditions for investors [1] Group 2: Analyst Background - The analysis is conducted by a stock analyst with over 20 years of experience in quantitative research, financial modeling, and risk management [1] - The analyst has a strong focus on equity valuation, market trends, and portfolio optimization to identify high-growth investment opportunities [1] - Previous experience includes a role as Vice President at Barclays, leading teams in model validation, stress testing, and regulatory finance [1] Group 3: Research Approach - The research approach combines rigorous risk management with a long-term perspective on value creation [1] - There is a particular interest in macroeconomic trends, corporate earnings, and financial statement analysis to provide actionable investment ideas [1]

Core Viewpoint - The article emphasizes the importance of conducting thorough personal research and due diligence before making investment decisions, highlighting the inherent risks involved in trading [3]. Group 1 - The analysis is intended solely for informational purposes and should not be interpreted as professional investment advice [3]. - There is a clear disclaimer regarding the lack of any stock or derivative positions in the companies mentioned, indicating a neutral stance [2]. - The article expresses the author's personal opinions and does not reflect the views of any affiliated organization [4].

Group 1 - The focus is on growth and dividend income as a strategy for retirement planning [1] - The portfolio is structured to generate monthly dividend income that grows through reinvestment and annual increases [1] Group 2 - The article emphasizes the importance of conducting personal research before making investment decisions [2] - It clarifies that the opinions expressed are personal and not intended as specific investment advice [2][3]

Core Viewpoint - Hims & Hers Health Inc. (HIMS) shares have decreased by 30% since the last rating, while the overall market has increased by 5% [1] Company Performance - The significant decline in HIMS shares indicates underperformance compared to the market [1] Analyst Perspective - The analyst has a long position in HIMS shares, indicating a personal investment interest in the company [2]

Group 1 - Hims & Hers Health Inc. (HIMS) shares have decreased by 30% since the last rating, while the market has increased by 5%, indicating underperformance [1] - The company is focused on providing health and wellness products, but recent stock performance raises concerns about its market position [1] Group 2 - The analyst has a beneficial long position in HIMS shares, indicating confidence in the company's potential despite recent stock declines [2] - The analysis reflects a broader investment strategy that includes technology and crypto opportunities, suggesting a diverse approach to market trends [2]

Core Insights - Hims & Hers Health, Inc. (HIMS) emphasizes the role of data and AI in creating a personalized healthcare experience, enhancing customer interactions and outcomes [1][6] - The company has launched Labs for tracking biomarkers and is investing in AI to improve clinical decision-making and care personalization [2][6] Company Developments - Hims & Hers introduced Labs, allowing customers to monitor key biomarkers and connect results to actionable plans developed by doctors [2] - The company is enhancing its MedMatch capabilities and AI workflows to improve diagnosis and care quality [6] Market Performance - Hims & Hers shares have increased by 24.2% over the past year, contrasting with a 5.2% decline in the industry [5] - The forward 12-month price-to-sales ratio for HIMS is 2.8X, lower than the industry average of 4.6X but higher than its three-year median of 2.6X [9] Earnings Estimates - The Zacks Consensus Estimate predicts a 77.8% increase in HIMS' earnings per share from 2024 to 2025 [7] - Current estimates for HIMS' earnings per share for the next year are 0.59, reflecting a year-over-year growth of 22.33% [10]

Market Sentiment - The stock market mood at the beginning of 2026 is characterized by nervousness among investors [1] - There is skepticism regarding the ability of large-cap growth stocks to maintain high valuation premiums amid soft macroeconomic conditions [1] Analyst Background - Gary Alexander has extensive experience in covering technology companies on Wall Street and working in Silicon Valley [1] - He has served as an adviser to several seed-round startups and has been a contributor on Seeking Alpha since 2017 [1] - His insights are widely disseminated, being quoted in various web publications and featured on trading apps like Robinhood [1]

Core Viewpoint - Hims and Hers Health (HIMS) shares are experiencing a decline, with current trading at approximately $32.23, down by $0.82, indicating mixed sentiment in options trading [1] Options Trading Summary - Options volume is consistent with average levels, with 81,000 contracts traded, and calls outpacing puts, resulting in a put/call ratio of 0.73, compared to a typical level of 0.59 [1] - Implied volatility (IV30) has increased by 3.1 points, reaching 60.94, which is in the lowest 10% of observations over the past year, suggesting an expected daily price movement of $1.24 [1] - The put-call skew has flattened, indicating a modestly bullish sentiment among traders [1]

Core Insights - Investors with significant capital have adopted a bearish outlook on Hims & Hers Health (NYSE:HIMS) [1] - The sentiment among large investors is notably negative, with 47% bearish and only 22% bullish positions observed [3] Options Trading Activity - A total of 36 unusual options trades were identified for Hims & Hers Health, indicating heightened trading activity [2] - The total amount for put options reached $589,371, while call options totaled $1,546,938, suggesting a preference for bearish positions [3] Price Movements and Trends - Major market movers are focusing on a price range between $3.0 and $105.0 for Hims & Hers Health over the past three months [4] - The analysis of volume and open interest reveals significant liquidity and investor interest in options trading for Hims & Hers Health [5] Noteworthy Options Activity - Specific options trades include bearish call trades with strike prices ranging from $22.00 to $70.00, indicating a cautious sentiment among traders [9] - The total trade prices for notable options include $196.2K for a bearish call with a strike price of $70.00 and $157.0K for a neutral call with a strike price of $22.00 [9] Company Overview - Hims & Hers Health is a telehealth platform launched in 2017, providing treatment options for various health issues and has over 2 million subscribers [10] - The company operates without insurance, accepting direct payments from customers, and is available in all 50 states and select European markets [10] Market Status - An expert recently issued a rating for Hims & Hers Health with an average target price of $48.0, reflecting a cautious outlook [11][12] - The current trading volume stands at 7,499,720, with the stock price at $32.83, down by -0.64% [14]

Core Insights - Hims & Hers Health, Inc. (HIMS) integrates technology and clinical infrastructure to deliver personalized care at scale, utilizing a comprehensive end-to-end system that includes digital intake, electronic medical records, and prescription workflows [1][2] - The company has made targeted investments in data and AI to enhance clinical decision-making and improve patient routing, leading to more personalized treatment pathways [2][7] - Recent product launches, such as Labs, incorporate longitudinal diagnostic data into the care experience, reinforcing the connection between data, providers, and treatment decisions [3] Company Developments - Hims & Hers has expanded its platform into hormone health and weight management, leveraging its integrated technology and clinical systems to scale new specialties while maintaining a data-driven care model [3][7] - The Zacks Consensus Estimate for HIMS' 2025 earnings per share indicates a significant improvement of 77.8% from 2024 [8] - Hims & Hers shares have increased by 41.1% over the past year, outperforming the industry average growth of 2.7% [6] Valuation Metrics - Hims & Hers has a forward 12-month price-to-sales (P/S) ratio of 2.8X, which is lower than the industry average of 4.6X but higher than its three-year median of 2.6X [9] - The company currently holds a Zacks Rank 3 (Hold), indicating a neutral outlook [12]